Basic net loss per Class A common share has been calculated by dividing net loss for the period, adjusted for net loss attributable to non-controlling interests, by the weighted average number of Class A common shares outstanding during the period. In periods in which the Company reports a net loss attributable to Maravai LifeSciences Holdings, Inc., diluted net loss per Class A common share attributable to the Company is the same as basic net loss per Class A common share attributable to the Company, since dilutive equity instruments are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to Maravai LifeSciences Holdings, Inc. during each of the three and six months ended June 30, 2025 and 2024.

The following table presents the computation of basic and diluted net loss per Class A common share attributable to the Company for the periods presented (in thousands, except per share amounts):


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024

Net loss	$	(69,837)	$	(18,420)	$	(122,690)	$	(41,100)
Less: loss attributable to common non-controlling interests	30,246		8,631		53,154		19,233
Net loss attributable to Maravai LifeSciences Holdings, Inc.	$	(39,591)	$	(9,789)	$	(69,536)	$	(21,867)






Weighted average Class A common shares outstanding	144,236		135,842		143,833		134,088






Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted	$	(0.27)	$	(0.07)	$	(0.48)	$	(0.16)

Shares of Class B common stock do not share in the earnings or losses of the Company and are therefore not participating securities. As such, a separate presentation of basic and diluted net loss per share for Class B common stock under the two-class method has not been presented.

The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive for the periods presented (in thousands):


	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Restricted stock units	13,360	2,173	3,566	2,399

Stock options	4,550	4,021	4,550	4,021
Shares estimated to be purchased under the employee stock purchase plan	2,025	15	2,025	10
Shares of Class B common stock	110,684	110,684	110,684	110,684
Total	130,619	116,893	120,825	117,114

Shares underlying contingently issuable awards that have not met the necessary conditions as of the end of a reporting period are not included in the calculation of diluted net loss per Class A common share attributable to the Company for that period. The Company had contingently issuable performance stock units outstanding that did not meet the market and performance conditions as of June 30, 2025 and 2024, and therefore, were excluded from the calculation of diluted net loss per Class A common share attributable to the Company. The maximum number of potentially dilutive shares that could be issued upon vesting for such awards was 3.3 million as of June 30, 2025 and was an insignificant amount as of June 30, 2024. These share amounts were also excluded from the potentially dilutive securities in the table above.